2/10
BioItaLEE is a phase 3B trial which enrolled postmenopausal pts with endocrine-sensitive HR+/HER2− aBC receiving ribociclib/letrozole as first-line therapy and prospectively collect blood samples to investigate potential biomarkers of response and resistence
3/10
Thymidine kinase 1 (TK1) is an enzyme with a role in cell proliferation, and with downstream activity to CDK4/6 pathway 👉attractive marker of CDK4/6 inhibitor efficacy
TK1 activity can be measured in serum as a readout of tumor proliferation
4/10 TKa were assessed at baseline (D0), day 15 of cycle 1 (D15), day 1 of cycle 2 (C2D1) and at first imaging (FI, 12 weeks)
We evaluated the prognostic role of TKa level at baseline and the predictive role of TKa dynamics
5/10
High TKa (value >median) at baseline was associated with poor prognosis (HR for disease progression 2.21; 95% CI 1.45,3.37; p=0.0002)
👉Baseline TKa is a strong PROGNOSTIC factor
6/10
The PREDICTIVE role of TKa dynamics explored by defining three patterns (LOD=Limit Of Detection)
- Pattern 1: TKa <LOD at D15 and C2D1 (persistent suppression)
- Pattern 2: TKa <LOD at D15 and >LOD at C2D1 (reboud at C2D1)
- Pattern 3: TKa >LOD at D15 (primary resistence)
7/10
TKa dynamic patterns were strongly predictive of PFS
- Pattern 2 (reboud at C2D1) had worse PFS compared with P1 (persistent suppression) (HR 2.89; 95% CI 1.57,5.31;p=0.0006)
- Pattern 3 (primary resistance) had an even shorter PFS (HR 5.65; 95% CI 2.84,11.23;p<0.0001)
9/10
Take home messages (I)
In HR+/HER2− aBC treated with RIB + LET as first-line
👉Baseline TKa is PROGNOSTIC
👉TKa dynamic is PREDICTIVE
👉Baseline and dynamic TKa changes provided independent information
10/10
Take home messages (II)
👉Lack of TKa decrease at D15 identify patients with primary resistance
👉TKa rebound at C2D1 may indicate early tumor adaptation to RIB + LET (average prognosis)
👉Persistent TKa decrease identify pts with excellent prognosis
Confirmation warreted